IL117098A0 - Glycine antagonist pharmaceutical compositions - Google Patents

Glycine antagonist pharmaceutical compositions

Info

Publication number
IL117098A0
IL117098A0 IL11709896A IL11709896A IL117098A0 IL 117098 A0 IL117098 A0 IL 117098A0 IL 11709896 A IL11709896 A IL 11709896A IL 11709896 A IL11709896 A IL 11709896A IL 117098 A0 IL117098 A0 IL 117098A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
glycine antagonist
antagonist pharmaceutical
glycine
compositions
Prior art date
Application number
IL11709896A
Other languages
English (en)
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of IL117098A0 publication Critical patent/IL117098A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11709896A 1995-02-11 1996-02-09 Glycine antagonist pharmaceutical compositions IL117098A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9502695.1A GB9502695D0 (en) 1995-02-11 1995-02-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
IL117098A0 true IL117098A0 (en) 1996-06-18

Family

ID=10769456

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11709896A IL117098A0 (en) 1995-02-11 1996-02-09 Glycine antagonist pharmaceutical compositions

Country Status (18)

Country Link
US (2) US5886018A (hu)
EP (1) EP0809514A1 (hu)
JP (1) JPH10513464A (hu)
KR (1) KR19980702109A (hu)
AU (1) AU707220B2 (hu)
BR (1) BR9607433A (hu)
CA (1) CA2212041A1 (hu)
CZ (1) CZ252897A3 (hu)
EA (1) EA000211B1 (hu)
FI (1) FI973280A0 (hu)
GB (1) GB9502695D0 (hu)
HU (1) HUP9702448A2 (hu)
IL (1) IL117098A0 (hu)
NO (1) NO973656L (hu)
NZ (1) NZ300937A (hu)
PL (1) PL321734A1 (hu)
WO (1) WO1996024376A1 (hu)
ZA (1) ZA961051B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US20040019075A1 (en) * 2002-05-29 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New formulation for the parenteral application of crobenetine
JP2007517056A (ja) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールdaao阻害剤
NZ554779A (en) 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―2―カルボキシレート化合物類を含有するcns疾患治療用組成物
WO1992001670A1 (en) * 1990-07-16 1992-02-06 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition

Also Published As

Publication number Publication date
AU4622896A (en) 1996-08-27
FI973280A (fi) 1997-08-08
NZ300937A (en) 1999-02-25
FI973280A0 (fi) 1997-08-08
NO973656D0 (no) 1997-08-08
HUP9702448A2 (hu) 1999-10-28
US5886018A (en) 1999-03-23
BR9607433A (pt) 1998-05-26
NO973656L (no) 1997-10-08
PL321734A1 (en) 1997-12-22
CZ252897A3 (cs) 1998-03-18
GB9502695D0 (en) 1995-03-29
AU707220B2 (en) 1999-07-08
JPH10513464A (ja) 1998-12-22
ZA961051B (en) 1996-09-11
EA000211B1 (ru) 1998-12-24
MX9706044A (es) 1998-06-28
US6020359A (en) 2000-02-01
EP0809514A1 (en) 1997-12-03
KR19980702109A (ko) 1998-07-15
WO1996024376A1 (en) 1996-08-15
EA199700095A1 (ru) 1998-02-26
CA2212041A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
HU9601698D0 (en) Pharmaceutical composition
EG24118A (en) Pharmaceutical compositions
ZA967827B (en) Pharmaceutical compositions
HUT74746A (en) Pharmaceutical compositions containing p antagonist
GB9519667D0 (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
ZA962214B (en) Pharmaceutical composition
GB9610359D0 (en) Pharmaceutical compositions
ZA963590B (en) Pharmaceutical composition
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
ZA96525B (en) Novel pharmaceutical compositions
IL117098A0 (en) Glycine antagonist pharmaceutical compositions
ZA9610426B (en) Pharmaceutical composition
GB9606429D0 (en) Pharmaceutical compositions
ZA964193B (en) Pharmaceutical composition
GB9613457D0 (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
HUP9602822A2 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
GB9525955D0 (en) Improved pharmaceutical compositions
HU0500763D0 (en) Pharmaceutical compositions
GB9511480D0 (en) Pharmaceutical compositions
GB9506301D0 (en) Pharmaceutical compositions